Get the Stockscreener App
23.12
3.47%
-0.83
Pre-market:
22.80
-0.32
-1.38%
Beam Therapeutics Inc stock is traded at $23.12, with a volume of 5.32M.
It is down -3.47% in the last 24 hours and down -21.92% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
See More
Previous Close:
$23.95
Open:
$24.4
24h Volume:
5.32M
Relative Volume:
2.84
Market Cap:
$2.35B
Revenue:
$139.74M
Net Income/Loss:
$-79.99M
P/E Ratio:
-22.76
EPS:
-1.0157
Net Cash Flow:
$-360.05M
1W Performance:
-8.69%
1M Performance:
-21.92%
6M Performance:
+0.13%
1Y Performance:
-0.43%
1-Day Range:
$23.07
$25.34
1-Week Range:
$23.07
$25.98
52-Week Range:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
23.12 | 2.35B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Canaccord Genuity | Buy |
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Death Cross: Can Beam Therapeutics Inc sustain its profitabilityQuarterly Portfolio Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Why did BEAM stock jump 10% in pre-market today? | Tap to know more | Inshorts - Inshorts
Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN
Beam To Extend Current Trial For Pivotal BEAM-302 Development - Citeline News & Insights
RBC Capital reiterates Beam Therapeutics stock rating on A1AT data By Investing.com - Investing.com Australia
Leerink raises Beam Therapeutics stock price target on AATD data - Investing.com
Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026 - MarketBeat
William Blair reiterates Beam Therapeutics stock rating on positive trial data - Investing.com India
Clear Street reiterates Beam Therapeutics stock rating on AATD data - Investing.com
Beam Therapeutics (BEAM) Sees Positive Data, Analyst Reaffirms B - GuruFocus
Why did BEAM stock jump 10% in pre-market today? - MSN
RBC Capital reiterates Beam Therapeutics stock rating on A1AT data - Investing.com
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels - Benzinga
Beam Therapeutics (BEAM) Advances Gene Therapy for Accelerated A - GuruFocus
Beam to move gene-editing drug in pivotal study (BEAM:NASDAQ) - Seeking Alpha
Beam Therapeutics (BEAM) Shares Promising BEAM-302 Trial Data - GuruFocus
Beam Therapeutics Says It Advances BEAM-302 to Pivotal Stage With 60 mg Dose Selection - marketscreener.com
Why Did BEAM Stock Jump 10% In Pre-Market Today? - Stocktwits
Beam Therapeutics stock jumps on positive trial data - Investing.com
Beam Therapeutics stock jumps on positive trial data By Investing.com - Investing.com Australia
BEAM: BEAM-302 at 60 mg delivers durable, functional AAT restoration and strong safety in AATD - TradingView
Beam Therapeutics Reports Positive Phase 1/2 Trial Results for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Selecting 60 mg as Optimal Dose for Pivotal Development - Quiver Quantitative
Beam Therapeutics selects 60 mg dose for AATD gene therapy trial - Investing.com
One gene-editing dose kept patients above protective protein levels - Stock Titan
Guidance Update: How does Beam Therapeutics Inc perform in inflationary periodsQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Beam Therapeutics Inc. (BEAM) reports Q4 loss, beats revenue estimates - MSN
Aug Retail: Is Beam Therapeutics Inc in a long term uptrend2026 Market Overview & Pattern Based Trade Signal System - baoquankhu1.vn
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
(BEAM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS) - The Globe and Mail
Farallon Capital Management LLC Purchases 50,000 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. $BEAM is Casdin Capital LLC's 9th Largest Position - MarketBeat
Integral Health Asset Management LLC Decreases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - The Globe and Mail
H.C. Wainwright Keeps Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
BEAM.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating - MSN
Liquidity Mapping Around (BEAM) Price Events - Stock Traders Daily
According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019. - Bitget
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit - TipRanks
Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd - marketscreener.com
HC Wainwright Predicts Weaker Earnings for Beam Therapeutics - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
ARK Investment Boosts Stake in Beam Therapeutics - National Today
Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Earnings Call Highlights PKU Pivot - TipRanks
What is HC Wainwright's Forecast for BEAM Q1 Earnings? - MarketBeat
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):